Robinson Clark Raymond, Habib Alma, Klomjit Nattawat, Cao Qing, Holtan Shernan Grace
Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Department of Hematology, The Ohio State University, Columbus, OH, United States.
Front Transplant. 2024 Mar 18;3:1352413. doi: 10.3389/frtra.2024.1352413. eCollection 2024.
The Simplified Comorbidity Index (SCI) is a recently published 5-component, pre-transplant tool to predict non-relapse mortality (NRM) in allogeneic hematopoietic cell transplantation (alloHCT) patients. The SCI captures chronic kidney disease (CKD) using estimated glomerular filtration rate (eGFR) based on the CKD-EPI equation (KDIGO 2021 CKD-EPI), which may be more sensitive to predict risk of NRM than the creatinine cut-off in the 16-component, Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI). We retrospectively assessed the ability of the SCI to risk-stratify patients and the impact of acute kidney injury (AKI) to NRM in adults who underwent alloHCT at the University of Minnesota. We included 373 patients who underwent their first alloHCT between 2015 and 2019. Through multivariate analysis, we found that patients with an SCI of greater than 4 had a higher risk of NRM. Additionally, we noted that AKIs stages 2-3 prior to day +100 was independently associated with a 3-fold greater NRM than patients who did not experience clinically significant AKI.
简化合并症指数(SCI)是一种最近发表的、包含5个组成部分的移植前工具,用于预测异基因造血细胞移植(alloHCT)患者的非复发死亡率(NRM)。SCI使用基于CKD-EPI方程(KDIGO 2021 CKD-EPI)的估计肾小球滤过率(eGFR)来评估慢性肾脏病(CKD),与16个组成部分的造血细胞移植合并症指数(HCT-CI)中的肌酐临界值相比,它在预测NRM风险方面可能更敏感。我们回顾性评估了SCI对患者进行风险分层的能力,以及急性肾损伤(AKI)对明尼苏达大学接受alloHCT的成年患者NRM的影响。我们纳入了2015年至2019年间接受首次alloHCT的373例患者。通过多变量分析,我们发现SCI大于4的患者NRM风险更高。此外,我们注意到移植后100天内发生2-3期AKI的患者,其NRM比未发生具有临床意义的AKI的患者高3倍。